| Tucatinib studied in …STUDIED_INderived55 of 55show fewer |
|---|
| → studied in | NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04721977Phase 2 · active not recruiting A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001) · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07413939Phase 2/Phase 3 · recruiting RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05868226Phase 1/Phase 2 · recruiting PRE-ISPY Phase I/II Oncology Platform Program · 55 trials list this drug (33 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07768358Phase 4 · not yet recruiting Tucatinib Continuation Study · 55 trials list this drug (33 active) | — | — | Lung Non-Small Cell Carcinoma,Malignant Colorectal Neoplasm,HER2-Positive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579380Phase 2 · active not recruiting Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations · 55 trials list this drug (33 active) | — | — | Urinary Tract Neoplasm,Lung Non-Small Cell Carcinoma,Uterine Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975647Phase 3 · active not recruiting A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05253651Phase 3 · recruiting A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer · 55 trials list this drug (33 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06157892Phase 2 · active not recruiting A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors · 55 trials list this drug (33 active) | — | — | Breast Neoplasm,Gastric Neoplasm,Malignant Breast Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05673928Phase 2 · recruiting A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) · 55 trials list this drug (33 active) | — | — | Solid Neoplasm,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05458674Phase 2 · active not recruiting Tucatinib+Trastuzumab+Eribulin in HER2+ MBC · 55 trials list this drug (33 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06239467Phase 1 · active not recruiting First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer · 55 trials list this drug (33 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05323955Phase 2 · active not recruiting Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04457596Phase 3 · active not recruiting T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial · 55 trials list this drug (33 active) | — | — | Breast Carcinoma,Invasive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07318389early Phase 1 · not yet recruiting ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · 55 trials list this drug (33 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06686394Phase 1/Phase 2 · recruiting Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) · 55 trials list this drug (33 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672524Phase 2 · recruiting A Study of Tucatinib and Trastuzumab in People With Rectal Cancer · 55 trials list this drug (33 active) | — | — | Rectal Neoplasm,Malignant Rectal Neoplasm,Rectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319873Phase 1/Phase 2 · active not recruiting Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer · 55 trials list this drug (33 active) | — | — | Invasive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07494448Phase 1/Phase 2 · not yet recruiting Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer · 55 trials list this drug (33 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03297606Phase 2 · recruiting Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) · 55 trials list this drug (33 active) | — | — | Solid Neoplasm,Multiple Myeloma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04539938Phase 2 · completed A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05748834Phase 2 · recruiting Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05230810Phase 1/Phase 2 · active not recruiting Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. · 55 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05382364Phase 1 · active not recruiting Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002) · 55 trials list this drug (33 active) | — | — | Breast Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04430738Phase 2 · active not recruiting Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers · 55 trials list this drug (33 active) | — | — | Cholangiocarcinoma,Colorectal Carcinoma,Esophageal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06016387Phase 2 · recruiting Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07193394Phase 2 · recruiting Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05892068Phase 2 · active not recruiting A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05062889Phase 2 · suspended Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients · 55 trials list this drug (33 active) | — | — | Colon Neoplasm,Malignant Colon Neoplasm,RAS Wild-Type Colon Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961331completed Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer. · 55 trials list this drug (33 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583110Phase 2 · terminated Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04538742Phase 1/Phase 2 · active not recruiting A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05253911completed Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05800275Phase 2 · recruiting Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease · 55 trials list this drug (33 active) | — | — | Leptomeningeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041842Phase 2 · active not recruiting Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501979Phase 2 · terminated Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm,Leptomeningeal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04220203approved for marketing Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04789096Phase 2 · terminated Tucatinib Together With Pembrolizumab and Trastuzumab · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04499924Phase 2/Phase 3 · completed Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer · 55 trials list this drug (33 active) | — | — | Esophageal Adenocarcinoma,Gastric Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 55 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02892123Phase 1 · completed Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers · 55 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03043313Phase 2 · completed Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer · 55 trials list this drug (33 active) | — | — | Colorectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05356897Phase 2 · withdrawn Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study · 55 trials list this drug (33 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm,Colon Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06162559Phase 1 · recruiting Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06067776Phase 1 · not yet recruiting Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer · 55 trials list this drug (33 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02614794Phase 2 · completed A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04896320Phase 1/Phase 2 · withdrawn Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer. · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05091528Phase 1/Phase 2 · terminated A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma,HER2-Positive Gastric Adenocarcinoma,HER2-Positive Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05227131Phase 2 · withdrawn Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04512261Phase 1/Phase 2 · withdrawn TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03846583Phase 1 · withdrawn Tucatinib + Abemaciclib + Herceptin for HER2+ MBC · 55 trials list this drug (33 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01983501Phase 1 · completed A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer · 55 trials list this drug (33 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02025192Phase 1 · completed A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424473no longer available Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer · 55 trials list this drug (33 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |